O
OrbiMed Portfolio holdings
AUM
$3.98B
This Quarter Return
+15.41%
1 Year Return
+13.05%
3 Year Return
+159.74%
5 Year Return
+207.27%
10 Year Return
+1,027.33%
AUM
$5.46B
AUM Growth
+$5.46B
(+8.6%)
Cap. Flow
-$50.4M
Cap. Flow
% of AUM
-0.92%
Top 10 Holdings %
Top 10 Hldgs %
41.94%
Holding
129
New
17
Increased
19
Reduced
31
Closed
16
Top Buys
| 1 |
MBX
MBX Biosciences, Inc. Common Stock
MBX
|
$99M |
| 2 |
UnitedHealth
UNH
|
$39.2M |
| 3 |
Sarepta Therapeutics
SRPT
|
$38.5M |
| 4 |
Amgen
AMGN
|
$37.8M |
| 5 |
Universal Health Services
UHS
|
$35.7M |
Top Sells
| 1 |
Janux Therapeutics
JANX
|
$78.2M |
| 2 |
Tenet Healthcare
THC
|
$65M |
| 3 |
Vaxcyte
PCVX
|
$46.7M |
| 4 |
VRNA
Verona Pharma
VRNA
|
$41.4M |
| 5 |
Geron
GERN
|
$37.9M |
Sector Composition
| 1 | Healthcare | 99.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
scPharmaceuticals
SCPH
$296M
| $27.6M | 0.5% |
6,059,528
+500,000
| +9% | +$2.28M |
|
52
Vir Biotechnology
VIR
$765M
| $26.8M | 0.49% |
3,573,000
+1,252,898
| +54% | +$9.38M |
|
53
Phathom Pharmaceuticals
PHAT
$843M
| $26.2M | 0.48% |
+1,449,073
| New | +$26.2M |
|
54
CG Oncology
CGON
$2.19B
| $26.1M | 0.47% |
+691,114
| New | +$26.1M |
|
55
Dyne Therapeutics
DYN
$1.92B
| $25.4M | 0.46% |
708,400
| – | – |
|
56
C4 Therapeutics
CCCC
$182M
| $25M | 0.45% |
4,377,900
+2,864,842
| +189% | +$16.3M |
|
57
Mineralys Therapeutics
MLYS
$1.94B
| $24.3M | 0.44% |
2,002,939
-18,485
| -0.9% | -$224K |
|
58
Neuropace
NPCE
$310M
| $23.7M | 0.43% |
3,406,335
| – | – |
|
59
Immatics
IMTX
$662M
| $22.9M | 0.42% |
2,006,381
| – | – |
|
60
Rhythm Pharmaceuticals
RYTM
$6.75B
| $22.8M | 0.41% |
435,900
-268,942
| -38% | -$14.1M |
|
61
Prelude Therapeutics
PRLD
$69.1M
| $22.6M | 0.41% |
10,909,256
| – | – |
|
62
Apogee Therapeutics
APGE
$2.27B
| $22.3M | 0.4% |
379,130
| – | – |
|
63
Neumora Therapeutics
NMRA
$283M
| $19.8M | 0.36% |
1,500,000
| – | – |
|
|
SLRN
64
DELISTED
ACELYRIN
SLRN
| $19.7M | 0.36% |
4,001,711
| – | – |
|
65
Corbus Pharmaceuticals
CRBP
$121M
| $18.8M | 0.34% |
+912,552
| New | +$18.8M |
|
66
Tyra Biosciences
TYRA
$657M
| $18.1M | 0.33% |
768,638
| – | – |
|
67
Cullinan Oncology
CGEM
$456M
| $17.9M | 0.33% |
1,070,055
-77,600
| -7% | -$1.3M |
|
68
Lexicon Pharmaceuticals
LXRX
$392M
| $17.3M | 0.31% |
11,024,000
+5,177,900
| +89% | +$8.13M |
|
69
Structure Therapeutics
GPCR
$1.14B
| $16.8M | 0.31% |
383,705
+258,705
| +207% | +$11.4M |
|
70
Adicet Bio
ACET
$60.8M
| $16.5M | 0.3% |
11,447,140
| – | – |
|
71
Medpace
MEDP
$13.5B
| $15M | 0.27% |
+44,900
| New | +$15M |
|
72
ADC Therapeutics
ADCT
$370M
| $14.3M | 0.26% |
4,533,801
+216,977
| +5% | +$683K |
|
73
Gilead Sciences
GILD
$140B
| $12.7M | 0.23% |
+151,700
| New | +$12.7M |
|
74
BioNTech
BNTX
$24.1B
| $12.2M | 0.22% |
+103,000
| New | +$12.2M |
|
75
Acadia Pharmaceuticals
ACAD
$4.34B
| $11.8M | 0.21% |
+764,600
| New | +$11.8M |
|